CSL Limited
(ASX:CSL) has reached a $US64 million settlement regarding a United States antitrust class action filed by US and Puerto Rican hospital groups.
CSL says the settlement dismisses all claims and potential claims of class members against CSL in the lawsuit, as well as those against the Plasma Protein Therapeutics Association.
The settlement and $64 million sum are subject to approval in the US Federal Court and is expected to take several months.
Meanwhile, the group says the settlement will not change its expectation for net profit after tax growth from the guidance it provided during its full-year results in August.
CSL says the settlement represents a one-off charge reducing net profit expectations for fiscal 2014 by $US39 million.
CSL generated a net profit of $1.3 billion in the first half of fiscal 2013.
